Oryzon Genomics, S.A.announced the appointment of Douglas Faller, M.D., Ph.D., to the role of Global Chief Medical Officer. Dr. Faller has over 30 years of clinical hematology/oncology expertise and broad drug development experience in the design and execution of early to registrational clinical programs across oncology and rare diseases and will lead Oryzon's global clinical development strategy. Based in Boston, Dr. Faller will strengthen Oryzon's permanent presence in the US as it builds up strategic partnerships with US hospitals and research institutions to develop its pipeline and clinical programs. Dr. Faller's extensive scientific and clinical research experience in hematology and oncology, as well as in other non-oncological and rare diseases, will be key in developing Oryzon's portfolio.

He joins Oryzon from Takeda, where he was Executive Medical Director and Global Clinical Leader for more than 5 years. He was Professor of Medicine at Harvard Medical School, and subsequently he founded and served as first Director of Boston University Cancer Center where he was also Grunebaum Professor for Cancer Research, and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. He has founded several biotech companies, some of them currently listed in Nasdaq, and has previously served as the Chief Medical Officer and Chief Scientific Officer of Viracta Therapeutics Inc.